Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer
Ke Liu1,2,3, Xia Xue1,2,3, Haiming Qin4,5
1Henan Key Laboratory for Helicobacter Pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Background:
The gut microbiome has emerged as a critical modulator of cancer immunotherapy response. However, the mechanisms by which gut-associated metabolites influence checkpoint blockade efficacy in prostate cancer (PC) remain not fully explored. The study aimed to explore how gut metabolites regulate death-ligand 1 (PD-L1) blockade via exosomes and boost immune checkpoint inhibitors (ICIs) in PC.
Methods:
We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines and transgenic adenocarcinoma of the mouse prostate (TRAMP) models.
Results:
We identified two metabolites, 16(R)-Hydroxyeicosatetraenoic acid (16(R)-HETE) and 6-Keto-Prostaglandin E1 (6-Keto-PGE1), that positively correlated with the plasma exosomal PD-L1 levels. The in vitro experiments found that both 16(R)-HETE and 6-Keto-PGE1 can enhance PD-L1 expression at the mRNA, protein, and exosome levels in both human and mouse PC cell lines, which were also validated in vivo based on subcutaneous mouse models. Both metabolites significantly promoted the anti-PD-L1 efficacy against PC in situ on a TRAMP mouse model.
Conclusions:
Targeting the "gut-tumor metabolic axis" is a promising strategy to improve the efficacy of immune checkpoint inhibitors in tumors.
Insights
Two gut metabolites, 16(R)-HETE and 6-Keto-PGE1, enhance PD-L1 expression and boost immunotherapy efficacy in prostate cancer (PC). Targeting the gut-tumor metabolic axis improves immune checkpoint inhibitors (ICIs) in PC.
Area of Science:
- Oncology
- Immunology
- Metabolomics
Background:
- The gut microbiome significantly influences cancer immunotherapy response.
- Mechanisms linking gut metabolites to checkpoint blockade efficacy in prostate cancer (PC) are underexplored.
- Immune checkpoint inhibitors (ICIs) are crucial in cancer treatment, but their efficacy varies.
Purpose of the Study:
- To investigate how gut metabolites regulate programmed death-ligand 1 (PD-L1) blockade via exosomes.
- To explore the role of gut metabolites in enhancing immune checkpoint inhibitors (ICIs) efficacy in PC.
- To elucidate the gut-tumor metabolic axis in PC immunotherapy.
Main Methods:
- Integrated multi-omics analysis of 70 PC patients across five subgroups.
- In vitro validation in PC cell lines and in vivo studies using transgenic adenocarcinoma of the mouse prostate (TRAMP) models.
- Assessment of PD-L1 expression and immunotherapy treatment efficacy.
Main Results:
- Identified 16(R)-Hydroxyeicosatetraenoic acid (16(R)-HETE) and 6-Keto-Prostaglandin E1 (6-Keto-PGE1) correlating with plasma exosomal PD-L1.
- Both metabolites enhanced PD-L1 expression at multiple levels (mRNA, protein, exosome) in human and mouse PC cells.
- These metabolites significantly promoted anti-PD-L1 efficacy in PC models.
Conclusions:
- Targeting the gut-tumor metabolic axis offers a promising strategy for improving ICI efficacy.
- Gut metabolites play a direct role in modulating PD-L1 expression and immunotherapy response in PC.
- Further research into the gut-tumor metabolic axis could lead to novel therapeutic approaches for PC.
Related Concept Videos
Neuromuscular Junction And Blockade
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Self-Efficacy
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
Self-Evaluation: Self-Enhancement and Self-Verification


